(E)-2-methoxybenzaldehyde 5-(2,4-difluorophenyl)-2-furoylhydrazone | 1259371-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (E)-2-methoxybenzaldehyde 5-(2,4-difluorophenyl)-2-furoylhydrazone
• 英文别名: 5-(2,4-difluorophenyl)-N-[(E)-(2-methoxyphenyl)methylideneamino]furan-2-carboxamide
• CAS: 1259371-03-3
• 化学式: C₁₉H₁₄F₂N₂O₃
• 分子量: 356.329
• InChiKey: JDJRYVYZKJYJAP-SSDVNMTOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-(2,4-difluorophenyl)-2-furoylhydrazide 、 邻甲氧基苯甲醛 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以99.33%的产率得到(E)-2-methoxybenzaldehyde 5-(2,4-difluorophenyl)-2-furoylhydrazone
  参考文献：
  名称：

  New class of potent antitumor acylhydrazone derivatives containing furan

  摘要：

  A pair of chemical isomeric structures of N-acylhydrazone compounds I and II were designed and synthesized. The reaction was carried out with high diastereoselectivity to obtain one configurational isomer in excellent yields. The exact configuration and conformation of IIa and IIe were confirmed by the X-ray single crystal diffraction. The antitumor bioassay revealed that some compounds exhibited excellent activity against the selected cancer cell lines. In particular, IIf (IC50 =16.4 mu M) was better than doxorubicin (IC50=53.3 mu M) against human promyelocytic leukemic cells (HL-60). Their toxicities were predicted in silico. The results showed that compounds II were safe and eligible to be development candidates. IIf showed great promise as a novel lead compound for further anticancer discovery. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.09.007

文献信息

• New class of potent antitumor acylhydrazone derivatives containing furan
  作者：Zining Cui、Ying Li、Yun Ling、Juan Huang、Jingrong Cui、Ruiqing Wang、Xinling Yang

  DOI：10.1016/j.ejmech.2010.09.007

  日期：2010.12

  A pair of chemical isomeric structures of N-acylhydrazone compounds I and II were designed and synthesized. The reaction was carried out with high diastereoselectivity to obtain one configurational isomer in excellent yields. The exact configuration and conformation of IIa and IIe were confirmed by the X-ray single crystal diffraction. The antitumor bioassay revealed that some compounds exhibited excellent activity against the selected cancer cell lines. In particular, IIf (IC50 =16.4 mu M) was better than doxorubicin (IC50=53.3 mu M) against human promyelocytic leukemic cells (HL-60). Their toxicities were predicted in silico. The results showed that compounds II were safe and eligible to be development candidates. IIf showed great promise as a novel lead compound for further anticancer discovery. (C) 2010 Elsevier Masson SAS. All rights reserved.